摘要
儿童慢性乙型肝炎(CHB)患者主要是通过IFN和核苷类似物进行抗病毒治疗,首选方案为IFN治疗。部分患者采取单一IFN或IFN联合或序贯核苷类似物抗病毒治疗,可以达到HBsAg清除即临床治愈的效果。目前面临的挑战是如何应用基于IFN的个体化抗病毒治疗策略使CHB患儿获得更多的临床治愈。
Children with chronic hepatitis B(CHB)are primarily treated with antiviral therapy using interferon(IFN)and nucleoside(acid)analogues(NAs),and IFN treatment is preferred.Some children can achieve HBsAg clearance(clinical cure)after treatment of single IFN or IFN combined NAs or sequential therapy with IFN and NAs.At present,the challenge is how to apply an individualized antiviral therapy strategy based on IFN to achieve more clinical cure in children with CHB.
作者
朱世殊
董漪
Zhu Shishu;Dong Yi(The Children's Liver Disease Therapy and Research Center,the Fifth Medical Center of PLA General Hospital,Beijing 100039,China)
出处
《国际流行病学传染病学杂志》
CAS
2020年第6期479-483,共5页
International Journal of Epidemiology and Infectious Disease
关键词
儿童
慢性乙型肝炎
干扰素
核苷类似物
临床治愈
Child
Chronic hepatitis B
Interferon
Nucleoside(acid)analogues
Clinical cure
